SYSamuel Nee-Amugie Yartey

Samuel Nee-Amugie Yartey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel Nee-Amugie Yartey has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A systematic review and meta-analysis of hepatitis B virus drug resistance and escape mutations in low- and middle-income countries

    by Esther M. E. Asamoah, Anastasia A. Asantewaa, Samuel N.-A. Yartey, Nicholas I. Nii-Trebi, Eric S. Donkor

    Background: Hepatitis B virus (HBV) remains highly endemic in many low- and middle-income countries (LMICs), where challenges such as antiviral resistance and immune/vaccine-escape mutations complicate disease management. Objective: This review synthesizes current data on HBV drug resistance, including the prevalence and distribution of resistance-associated mutations (RAMs), vaccine-escape mutations (VEMs), and immune-escape mutations (IEMs) in LMICs. Design: Systematic review and meta-analysis. Data sources: PubMed, Scopus, and Web of Science. Methods: A systematic search was conducted from 2014 to 2025 (last search date: August 04, 2025), and data were extracted from eligible studies. A random-effects meta-analysis was conducted to estimate pooled resistance rates and prevalences. Results: A total of 43,834 participants from 47 studies conducted in 28 LMICs were included. The overall antiviral resistance rate was 7.87% (95% CI (5.13–11.11)), with very high heterogeneity ( I 2 = 99.7%). Lamivudine (3TC) and telbivudine (LdT) had the highest resistance rates. Asia consistently reported the greatest resistance, with rates of 32.45% for 3TC and 51.92% for LdT. In a subgroup analysis on economic regions, Lower-middle-income countries showed the highest pooled resistance rate at 10.61% (95% CI (5.21–17.51); I 2 = 96.9%). The most frequently detected RAMs were rtM204V/I, rtV173L, and rtL180M. The pooled prevalence of vaccine-escape mutations was 8.92% (95% CI (5.02–13.64); I 2 = 78.4%). Immune-escape mutations were much more common, with a pooled prevalence of 55.66% (95% CI (28.10–81.53); I 2 = 98.1%). The most prevalent mutations were sG145R/A/K, sQ129H/R, sD144E/A, sS143L/T, and sP120S/T. The pooled estimates in this study are reported and interpreted descriptively, given the substantial heterogeneity observed. Conclusion: The remarkably high drug resistance rates and prevalence of immune and vaccine-escape mutations suggest notable burdens of resistance, especially for drugs with low genetic barriers such as lamivudine and telbivudine, underscoring the growing challenges in achieving the WHO 2030 reduction goals, and highlighting the need for enhanced surveillance, adoption of potent antiviral regimens such as tenofovir disoproxil fumarate, and continuous vaccine efficacy monitoring. However, the results should be interpreted with caution due to the very high heterogeneity observed in the study. Trial registration: International prospective register of systematic reviews (PROSPERO) under the ID: CRD420251030302.

  • Open Access

    Antibiotic impact on human microecology in low- and middle-income countries: a systematic age-stratified review of gut and respiratory microbiome and resistome

    by Samuel Nee-Amugie Yartey, Aaron Awere-Duodu, Anastasia Akosua Asantewaa, Eric S. Donkor

    Background: Antibiotic exposure disrupts microbial communities in the gut and respiratory tract, causing functional changes that may have lasting health impacts and contribute to the spread of antibiotic resistance genes (ARGs) throughout life. However, age-stratified evidence of these effects, particularly in low- and middle-income countries (LMICs), remains limited. Objective: This systematic review assessed the impact of antibiotics on gut and respiratory microbiomes and resistomes in LMICs, with separate analyses for adults and children. Data sources: PubMed, Scopus, Web of Science, & ScienceDirect. Methods: A comprehensive literature search was conducted using a predefined search strategy and eligibility criteria to identify relevant studies from LMICs. Twenty-five studies met the inclusion criteria: 23 examined the gut microbiome, and 2 focused on the respiratory microbiome. Key outcomes included microbial diversity (alpha/beta/gamma), taxonomic shifts, resistome profiles, functional changes, and recovery potentials, stratified by age group and body site. Results: Antibiotic exposure was generally associated with reductions in microbial diversity and altered taxonomic composition, with children showing more pronounced and prolonged disruptions than adults. Analysis of resistome changes revealed a critical finding: while antibiotics consistently selected for ARGs matching the drug class administered, a substantial reservoir of non-matching, background ARGs, conferring resistance to beta-lactams, aminoglycosides, vancomycin, tetracyclines, was also highly prevalent across studies. This indicates a silent pre-existing resistome that is enriched by antibiotic pressure. ARGs were more abundant in adult resistomes, though functional changes occurred across age groups. Microbiome recovery was observed over time, but resistome recovery was limited. Conclusion: Antibiotic use significantly disturbs the gut and respiratory microbiomes and promotes ARG enrichment, especially in children, who demonstrate greater susceptibility and lower recovery potential. These findings emphasise the need for targeted antibiotic stewardship, improved microbiome recovery research, and enhanced resistome monitoring in LMICs. Trail registration: International Prospective Register of Systematic Reviews (PROSPERO), ID: CRD420250641394.